Biotest AG
XETRA:BIO2

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO2
Watchlist
Price: 43.02 EUR Market Closed
Market Cap: 1.7B EUR
Section:
 

Relative Value

BIO2 price has not been updated for more than 9 months. This may indicate that the stock has been delisted.

The Relative Value of one BIO2 stock under the Base Case scenario is hidden EUR. Compared to the current market price of 43.02 EUR, Biotest AG is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BIO2 Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.5
P/S
P/S
Price to Sales
2.5
vs History
55
vs Industry
76
Median 3Y
2.5
Median 5Y
2.6
Industry
7.8
Forward
2.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
7
Median 3Y
-24.3
Median 5Y
-31
Industry
24.1
Forward
27.3
More Details
110.5
P/OCF
P/OCF
Price to OCF
110.5
vs History
9
vs Industry
Median 3Y
18.4
Median 5Y
18.4
Industry
21.8
More Details
3 055.7
P/FCFE
P/FCFE
Price to FCFE
3 055.7
vs History
4
vs Industry
Median 3Y
-12.5
Median 5Y
-12.5
Industry
23.8
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
60
vs Industry
30
Median 3Y
3.3
Median 5Y
3.3
Industry
3.3
More Details
3.4
EV/S
EV/S
Enterprise Value to Sales
3.4
vs History
52
vs Industry
62
Median 3Y
3.4
Median 5Y
3.5
Industry
8
Forward
3
More Details
14.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.7
vs History
44
vs Industry
44
Median 3Y
14.7
Median 5Y
14.7
Industry
10.3
More Details
182.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
182.4
vs History
7
vs Industry
9
Median 3Y
17
Median 5Y
11.1
Industry
6.3
Forward
14.5
More Details
182.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
182.4
vs History
7
vs Industry
7
Median 3Y
16.6
Median 5Y
-38
Industry
6.7
Forward
20.1
More Details
150.7
EV/OCF
EV/OCF
Enterprise Value to OCF
150.7
vs History
9
vs Industry
Median 3Y
22.8
Median 5Y
22.8
Industry
7.9
More Details
150.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
150.7
vs History
9
vs Industry
Median 3Y
22.8
Median 5Y
22.8
Industry
6.3
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
57
vs Industry
49
Median 3Y
1.8
Median 5Y
1.8
Industry
5.5
More Details

Multiples Across Competitors

BIO2 Competitors Multiples
Biotest AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Biotest AG
XETRA:BIO2
1.6B EUR 2.5 -64.9 182.4 182.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 623 419.7 -159 807.1 -194 056.8 -191 842.4
US
Abbvie Inc
NYSE:ABBV
404.4B USD 6.8 172.2 16.6 23.6
US
Amgen Inc
NASDAQ:AMGN
178.3B USD 5 25.5 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.5B USD 5.3 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.6B USD 9.9 31.7 23.3 24.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 095.2 -534.6 -582.2 -566.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD 5.8 18.1 17.3 19.6
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.4 1 206.1 158.4 192.1
NL
argenx SE
XBRU:ARGX
44.1B EUR 14.4 33.9 58.5 60.1
P/S Multiple
Revenue Growth P/S to Growth
DE
Biotest AG
XETRA:BIO2
Average P/S: 3 056 871.3
2.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 623 419.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 095.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
DE
Biotest AG
XETRA:BIO2
Average P/E: 190.7
Negative Multiple: -64.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 807.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 206.1
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Biotest AG
XETRA:BIO2
Average EV/EBITDA: 55.6
182.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 056.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158.4
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Biotest AG
XETRA:BIO2
Average EV/EBIT: 61
182.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 842.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.6
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.1
N/A N/A
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A

See Also

Summary
BIO2 intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIO2 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIO2 stock valuation using valuation multiples.
Wall Street Estimates
BIO2 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIO2 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.